amlodipine has been researched along with Dyslipidemias in 34 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to determine the efficacy and tolerability of a fixed-dose SPC consisting of 5 mg amlodipine, 100 mg losartan, 20 mg rosuvastatin, and 10 mg ezetimibe (A/L/R/E) in patients with concomitant hypertension and dyslipidemia." | 9.69 | A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia. ( Ahn, Y; Chae, IH; Hong, SJ; Hong, TJ; Kang, DH; Kim, BK; Kim, H; Kim, HS; Kim, MC; Kim, MH; Kim, SH; Kim, SY; Kim, W; Rhee, MY, 2023) |
| "This multicenter, randomized, double-blind, parallel-group phase III clinical trial aimed to investigate the efficacy and safety of a rosuvastatin + amlodipine combination compared with that of rosuvastatin or amlodipine monotherapy in hypertensive patients with dyslipidemia." | 9.34 | A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension. ( Ahn, JC; Ahn, YK; Chang, K; Cho, EJ; Cho, KI; Kang, DH; Kim, M; Kim, SJ; Kim, SY; Kim, U; Kim, W; Kim, YJ; Lee, CH; Lee, SH; Park, CG; Shin, JH; Yu, CW, 2020) |
| "Fixed-dose combination therapy with telmisartan, amlodipine, and rosuvastatin is needed in patients with hypertension and dyslipidemia for better adherence and cost-effectiveness than free-equivalent combination therapies." | 9.30 | Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial. ( Ahn, Y; Chang, K; Cho, JM; Hong, SJ; Hyon, MS; Jeong, HS; Kang, WC; Kim, HS; Lee, JH; Pyun, WB, 2019) |
| "Being safe, the fixed-dose lisinopril and amlodipine combination is effective in lowering blood pressure in patients with hypertensive disease (HD) concurrent with coronary heart disease (CHD) or atherosclerotic changes in the carotid artery." | 9.19 | [A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease]. ( Galeeva, ZM; Galiavich, AS, 2014) |
| "This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function." | 9.15 | The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011) |
| "Early and sustained improvement in small artery compliance was observed following coadministration of amlodipine and atorvastatin, thus demonstrating a vascular benefit with simultaneous treatment of hypertension and dyslipidemia." | 9.14 | Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. ( Cohn, JN; Grimm, R; Houston, M; Neutel, J; Smith, DH; Sun, W; Weinberger, MH; Wilson, DJ, 2009) |
| " The Respond trial assessed whether combining amlodipine to treat hypertension and atorvastatin to treat dyslipidemia affected the action of either monotherapy." | 9.12 | A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. ( Dykstra, G; Gillen, D; Harvey, P; Herfert, O; Jukema, JW; Preston, RA; Sun, F, 2007) |
| "The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia." | 9.12 | Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. ( Bakris, GL; Ferrera, D; Flack, JM; Houston, MC; Lee, E; Messerli, FH; Neutel, JM; Petrella, RJ; Sun, W, 2006) |
| "- The aim was to evaluate the efficacy of a single-pill combination of atorvastatin/amlodipine in patients with arterial hypertension, dyslipidemia and moderate to high cardiovascular risk." | 7.88 | EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA. ( Georgieva Torbova-Gigova, S; Ivanov Manov, E; Margaritov Runev, N; Naydenov Naydenov, S, 2018) |
| "We assessed effect of 6-weeks therapy with atorvastatin on parameters of lipid metabolism and some hemorheological characteristics in 27 patients with arterial hypertension (AH) and dyslipoproteinemia (DLP)." | 7.76 | [Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia]. ( Abrashkina, ED; Nazarova, OA; Pakhrova, OA; Shaalali, N; Shutemova, EA, 2010) |
| " There was no significant difference in the adverse events rates between RSV 10 mg/AML 5 mg, RSV 20 mg/AML 5 mg, and ATV 20 mg/AML 5 mg." | 7.30 | Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia. ( Bae, HJ; Cho, EJ; Choi, JY; Han, KR; Hong, BK; Hong, SP; Hyon, MS; Jin, HY; Jung, HW; Kim, CY; Kim, KS; Kim, SY; Kim, U; Lee, JB; Lee, KH; Lee, KJ; Lee, SR; Lee, SY; Nam, CW; Park, CG; Park, SJ; Park, TH; Rhee, MY; Ryu, JK; Seol, SH; Shin, JH; Yang, DH; Yu, GW, 2023) |
| " The secondary efficacy variables were changes in MSSBP, mean sitting diastolic blood pressure (MSDBP), LDL cholesterol and other lipid levels at 4 weeks and 8 weeks, as well as observed adverse events during follow-up." | 6.94 | Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia. ( Ahn, JC; Chae, IH; Cho, EJ; Cho, JM; Cho, Y; Choi, SY; Han, KH; Hong, SJ; Hong, SP; Hwang, J; Hyon, MS; Jin, X; Kim, H; Kim, HS; Kim, JH; Kim, MH; Kim, PJ; Kim, WS; Kwon, K; Lee, H; Lee, HC; Lee, JH; Lee, K; Lee, SH; Park, CG; Rhee, MY; Seo, JS; Shin, JH; Sung, JH; Sung, KC; Yoo, BS, 2020) |
| " The bioavailability of amlodipine and atorvastatin with a single-tablet, fixed-dose amlodipine/atorvastatin combination was not significantly different to that with coadministered separate amlodipine and atorvastatin tablets." | 6.46 | Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. ( Curran, MP, 2010) |
| "We aimed to determine the efficacy and tolerability of a fixed-dose SPC consisting of 5 mg amlodipine, 100 mg losartan, 20 mg rosuvastatin, and 10 mg ezetimibe (A/L/R/E) in patients with concomitant hypertension and dyslipidemia." | 5.69 | A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia. ( Ahn, Y; Chae, IH; Hong, SJ; Hong, TJ; Kang, DH; Kim, BK; Kim, H; Kim, HS; Kim, MC; Kim, MH; Kim, SH; Kim, SY; Kim, W; Rhee, MY, 2023) |
| "Hypertension and dyslipidemia are important risk factors for cardiovascular disease." | 5.56 | Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia. ( Chu, PH; Chu, YC; Hsiao, FC; Kao, YW; Lin, CP; Lin, YS; Tung, YC; Yang, CH, 2020) |
| "This multicenter, randomized, double-blind, parallel-group phase III clinical trial aimed to investigate the efficacy and safety of a rosuvastatin + amlodipine combination compared with that of rosuvastatin or amlodipine monotherapy in hypertensive patients with dyslipidemia." | 5.34 | A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension. ( Ahn, JC; Ahn, YK; Chang, K; Cho, EJ; Cho, KI; Kang, DH; Kim, M; Kim, SJ; Kim, SY; Kim, U; Kim, W; Kim, YJ; Lee, CH; Lee, SH; Park, CG; Shin, JH; Yu, CW, 2020) |
| "Fixed-dose combination therapy with telmisartan, amlodipine, and rosuvastatin is needed in patients with hypertension and dyslipidemia for better adherence and cost-effectiveness than free-equivalent combination therapies." | 5.30 | Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial. ( Ahn, Y; Chang, K; Cho, JM; Hong, SJ; Hyon, MS; Jeong, HS; Kang, WC; Kim, HS; Lee, JH; Pyun, WB, 2019) |
| "Being safe, the fixed-dose lisinopril and amlodipine combination is effective in lowering blood pressure in patients with hypertensive disease (HD) concurrent with coronary heart disease (CHD) or atherosclerotic changes in the carotid artery." | 5.19 | [A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease]. ( Galeeva, ZM; Galiavich, AS, 2014) |
| " In this study, we investigated the effects of valsartan and amlodipine on the lipid profile in patients with newly diagnosed essential hypertension." | 5.17 | An additional LDL-lowering effect of amlodipine; not only an antihypertensive? ( Akhan, M; Arslan, E; Arslan, Z; Ay, SA; Balta, S; Bulucu, F; Cakar, M; Celik, T; Demirbas, S; Demirkol, S; Karaman, M; Saglam, K; Sarlak, H, 2013) |
| "This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function." | 5.15 | The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011) |
| "Single-pill amlodipine/atorvastatin targets the two most common modifiable cardiovascular risk factors, hypertension and dyslipidaemia." | 5.14 | International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. ( Bauer, B; da Silva, PM; Feldman, RD; Genest, J; Gensini, G; Harvey, P; Jenssen, TG; John Mancini, GB; Manolis, AJ; Richard Hobbs, FD, 2009) |
| "The Gemini-AALA (Australia, Asia, Latin America, Africa/Middle East) study evaluated the efficacy and safety of single-pill amlodipine/atorvastatin (Caduet) for the treatment of patients of diverse ethnicity with concomitant hypertension and dyslipidaemia." | 5.14 | Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). ( Aguilar-Salinas, CA; Chaves, H; Chopra, P; Erdine, S; Guindy, R; Howes, LG; Moller, RA; Ro, YM; Schou, IM; Tse, HF, 2009) |
| "Early and sustained improvement in small artery compliance was observed following coadministration of amlodipine and atorvastatin, thus demonstrating a vascular benefit with simultaneous treatment of hypertension and dyslipidemia." | 5.14 | Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. ( Cohn, JN; Grimm, R; Houston, M; Neutel, J; Smith, DH; Sun, W; Weinberger, MH; Wilson, DJ, 2009) |
| "The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia." | 5.12 | Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. ( Bakris, GL; Ferrera, D; Flack, JM; Houston, MC; Lee, E; Messerli, FH; Neutel, JM; Petrella, RJ; Sun, W, 2006) |
| " The Respond trial assessed whether combining amlodipine to treat hypertension and atorvastatin to treat dyslipidemia affected the action of either monotherapy." | 5.12 | A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. ( Dykstra, G; Gillen, D; Harvey, P; Herfert, O; Jukema, JW; Preston, RA; Sun, F, 2007) |
| "- The aim was to evaluate the efficacy of a single-pill combination of atorvastatin/amlodipine in patients with arterial hypertension, dyslipidemia and moderate to high cardiovascular risk." | 3.88 | EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA. ( Georgieva Torbova-Gigova, S; Ivanov Manov, E; Margaritov Runev, N; Naydenov Naydenov, S, 2018) |
| "Purpose - studying of clinical efficiensy of the combined therapy (Amlodipin with Valsartan and fibrates) in hypertensive patients with dyslipidemia." | 3.88 | [THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA]. ( Gegeshidze, N; Kapetivadze, V; Lazashvili, T; Maglapheridze, Z; Tabukashvili, R; Tchaava, K, 2018) |
| "the Indonesian subset of the EXCITE (clinical EXperience of amlodIpine and valsarTan in hypErtension) study, which was a multinational, prospective, observational, open study in hypertensive patients treated with Aml/Val SPC for 26 weeks." | 3.81 | Clinical Effectiveness, Safety and Tolerability of Amlodipine/Valsartan in Hypertensive Patients: the Indonesian Subset of the EXCITE Study. ( Abdillah, A; Kalim, H; Setiawati, A, 2015) |
| "We assessed effect of 6-weeks therapy with atorvastatin on parameters of lipid metabolism and some hemorheological characteristics in 27 patients with arterial hypertension (AH) and dyslipoproteinemia (DLP)." | 3.76 | [Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia]. ( Abrashkina, ED; Nazarova, OA; Pakhrova, OA; Shaalali, N; Shutemova, EA, 2010) |
| " There was no significant difference in the adverse events rates between RSV 10 mg/AML 5 mg, RSV 20 mg/AML 5 mg, and ATV 20 mg/AML 5 mg." | 3.30 | Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia. ( Bae, HJ; Cho, EJ; Choi, JY; Han, KR; Hong, BK; Hong, SP; Hyon, MS; Jin, HY; Jung, HW; Kim, CY; Kim, KS; Kim, SY; Kim, U; Lee, JB; Lee, KH; Lee, KJ; Lee, SR; Lee, SY; Nam, CW; Park, CG; Park, SJ; Park, TH; Rhee, MY; Ryu, JK; Seol, SH; Shin, JH; Yang, DH; Yu, GW, 2023) |
| " The secondary efficacy variables were changes in MSSBP, mean sitting diastolic blood pressure (MSDBP), LDL cholesterol and other lipid levels at 4 weeks and 8 weeks, as well as observed adverse events during follow-up." | 2.94 | Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia. ( Ahn, JC; Chae, IH; Cho, EJ; Cho, JM; Cho, Y; Choi, SY; Han, KH; Hong, SJ; Hong, SP; Hwang, J; Hyon, MS; Jin, X; Kim, H; Kim, HS; Kim, JH; Kim, MH; Kim, PJ; Kim, WS; Kwon, K; Lee, H; Lee, HC; Lee, JH; Lee, K; Lee, SH; Park, CG; Rhee, MY; Seo, JS; Shin, JH; Sung, JH; Sung, KC; Yoo, BS, 2020) |
| " The primary objective of the study was to determine the effect of once-daily dosing of a combination therapy for blood pressure (BP) and dyslipidemia using home BP monitoring on reaching clinical BP and the effect of daily dosing of combination therapy on reaching lipid goals." | 2.76 | Improving adherence with amlodipine/atorvastatin therapy: IMPACT study. ( Crabbe, A; Delkhah, Y; Jones, J; Leonard, D; Nesbitt, S; Oliver, S, 2011) |
| " The bioavailability of amlodipine and atorvastatin with a single-tablet, fixed-dose amlodipine/atorvastatin combination was not significantly different to that with coadministered separate amlodipine and atorvastatin tablets." | 2.46 | Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. ( Curran, MP, 2010) |
| "Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular risk factors which together cause an increase in coronary heart disease-related events that is more than simply additive for anticipated event rates with each condition." | 2.45 | Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. ( Bangalore, S; Devabhaktuni, M, 2009) |
| "Hypertension and dyslipidemia are important risk factors for cardiovascular disease." | 1.56 | Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia. ( Chu, PH; Chu, YC; Hsiao, FC; Kao, YW; Lin, CP; Lin, YS; Tung, YC; Yang, CH, 2020) |
| "5%) were adherent to the therapy (PDC ≥ 80%); among them, a small percentage required dosage modification." | 1.51 | Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy. ( Degli Esposti, L; Gambera, M; Nati, G; Perone, F; Perrone, V; Tagliabue, PF; Veronesi, C; Volpe, M, 2019) |
| "Our objective was to describe prescribing patterns of simvastatin in combination with medications known to increase the risk of myopathies following updated product labeling dosing restrictions in June 2011." | 1.42 | Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database. ( Ghushchyan, V; Nair, K; Saseen, JJ; Tuchscherer, RM, 2015) |
| "Cardiovascular diseases are the leading cause of death worldwide." | 1.39 | Fixed combination of amlodipine/atorvastatin: from mechanisms to trials. ( Ivanovic, B; Tadic, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (29.41) | 29.6817 |
| 2010's | 18 (52.94) | 24.3611 |
| 2020's | 6 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, MC | 1 |
| Ahn, Y | 2 |
| Kim, MH | 2 |
| Kim, SY | 3 |
| Hong, TJ | 1 |
| Rhee, MY | 3 |
| Kim, SH | 1 |
| Hong, SJ | 3 |
| Kim, H | 2 |
| Kim, W | 2 |
| Chae, IH | 2 |
| Kang, DH | 2 |
| Kim, BK | 1 |
| Kim, HS | 3 |
| Jung, HW | 1 |
| Kim, CY | 1 |
| Hong, SP | 2 |
| Bae, HJ | 1 |
| Choi, JY | 1 |
| Ryu, JK | 1 |
| Lee, JB | 1 |
| Lee, KH | 1 |
| Han, KR | 1 |
| Yang, DH | 1 |
| Park, CG | 3 |
| Yu, GW | 1 |
| Park, SJ | 1 |
| Hyon, MS | 3 |
| Shin, JH | 3 |
| Hong, BK | 1 |
| Jin, HY | 1 |
| Lee, SY | 1 |
| Seol, SH | 1 |
| Lee, SR | 1 |
| Lee, KJ | 1 |
| Cho, EJ | 4 |
| Nam, CW | 1 |
| Park, TH | 1 |
| Kim, U | 2 |
| Kim, KS | 1 |
| Perrone, V | 1 |
| Veronesi, C | 1 |
| Gambera, M | 1 |
| Nati, G | 1 |
| Perone, F | 1 |
| Tagliabue, PF | 1 |
| Degli Esposti, L | 1 |
| Volpe, M | 1 |
| Sofogianni, A | 1 |
| Tziomalos, K | 1 |
| Chang, K | 2 |
| Ahn, JC | 2 |
| Yu, CW | 1 |
| Cho, KI | 1 |
| Kim, YJ | 1 |
| Lee, SH | 2 |
| Kim, SJ | 1 |
| Ahn, YK | 1 |
| Lee, CH | 1 |
| Kim, M | 1 |
| Lin, CP | 1 |
| Tung, YC | 1 |
| Hsiao, FC | 1 |
| Yang, CH | 1 |
| Kao, YW | 1 |
| Lin, YS | 1 |
| Chu, YC | 1 |
| Chu, PH | 1 |
| Jin, X | 1 |
| Han, KH | 1 |
| Sung, JH | 1 |
| Cho, JM | 2 |
| Lee, HC | 1 |
| Choi, SY | 1 |
| Lee, K | 1 |
| Kim, WS | 1 |
| Kim, JH | 2 |
| Yoo, BS | 1 |
| Lee, JH | 2 |
| Kim, PJ | 1 |
| Sung, KC | 1 |
| Hwang, J | 1 |
| Kwon, K | 1 |
| Seo, JS | 1 |
| Lee, H | 1 |
| Cho, Y | 1 |
| Tabukashvili, R | 1 |
| Kapetivadze, V | 1 |
| Tchaava, K | 1 |
| Gegeshidze, N | 1 |
| Lazashvili, T | 1 |
| Maglapheridze, Z | 1 |
| Jeong, HS | 1 |
| Pyun, WB | 1 |
| Kang, WC | 1 |
| Naydenov Naydenov, S | 1 |
| Margaritov Runev, N | 1 |
| Ivanov Manov, E | 1 |
| Georgieva Torbova-Gigova, S | 1 |
| Ivanovic, B | 1 |
| Tadic, M | 1 |
| Sutradhar, S | 3 |
| Yunis, C | 3 |
| Westergaard, M | 1 |
| Tuchscherer, RM | 1 |
| Nair, K | 1 |
| Ghushchyan, V | 1 |
| Saseen, JJ | 1 |
| Galeeva, ZM | 1 |
| Galiavich, AS | 1 |
| Setiawati, A | 1 |
| Kalim, H | 1 |
| Abdillah, A | 1 |
| Ferket, BS | 1 |
| Hunink, MG | 1 |
| Khanji, M | 1 |
| Agarwal, I | 1 |
| Fleischmann, KE | 1 |
| Petersen, SE | 1 |
| Erdine, S | 1 |
| Ro, YM | 1 |
| Tse, HF | 1 |
| Howes, LG | 1 |
| Aguilar-Salinas, CA | 1 |
| Chaves, H | 1 |
| Guindy, R | 1 |
| Chopra, P | 1 |
| Moller, RA | 1 |
| Schou, IM | 1 |
| Cohn, JN | 1 |
| Wilson, DJ | 1 |
| Neutel, J | 1 |
| Houston, M | 1 |
| Weinberger, MH | 1 |
| Grimm, R | 2 |
| Smith, DH | 1 |
| Sun, W | 2 |
| Neutel, JM | 2 |
| Bestermann, WH | 1 |
| Dyess, EM | 1 |
| Graff, A | 1 |
| Kursun, A | 2 |
| Richard Hobbs, FD | 1 |
| Gensini, G | 2 |
| John Mancini, GB | 1 |
| Manolis, AJ | 2 |
| Bauer, B | 2 |
| Genest, J | 2 |
| Feldman, RD | 1 |
| Harvey, P | 3 |
| Jenssen, TG | 2 |
| da Silva, PM | 2 |
| Devabhaktuni, M | 1 |
| Bangalore, S | 1 |
| Curran, MP | 1 |
| Malik, M | 1 |
| Lopatin, IuM | 1 |
| Abrashkina, ED | 1 |
| Shaalali, N | 1 |
| Pakhrova, OA | 1 |
| Shutemova, EA | 1 |
| Nazarova, OA | 1 |
| Yamamoto, K | 1 |
| Ozaki, H | 1 |
| Takayasu, K | 1 |
| Akehi, N | 1 |
| Fukui, S | 1 |
| Sakai, A | 1 |
| Kodama, M | 1 |
| Shimonagata, T | 1 |
| Kobayashi, K | 1 |
| Ota, M | 1 |
| Horiguchi, Y | 1 |
| Ebisuno, S | 1 |
| Katsube, Y | 1 |
| Yamazaki, T | 1 |
| Ohtsu, H | 1 |
| Hori, M | 1 |
| Oliver, S | 1 |
| Jones, J | 1 |
| Leonard, D | 1 |
| Crabbe, A | 1 |
| Delkhah, Y | 1 |
| Nesbitt, S | 1 |
| Delgado-Montero, A | 1 |
| Zamorano, JL | 1 |
| Arslan, Z | 1 |
| Ay, SA | 1 |
| Karaman, M | 1 |
| Cakar, M | 1 |
| Celik, T | 1 |
| Balta, S | 1 |
| Akhan, M | 1 |
| Sarlak, H | 1 |
| Arslan, E | 1 |
| Demirbas, S | 1 |
| Demirkol, S | 1 |
| Bulucu, F | 1 |
| Saglam, K | 1 |
| Hobbs, FD | 1 |
| Mancini, GB | 1 |
| Böhler, S | 1 |
| Feldman, R | 1 |
| Metcalfe, M | 1 |
| Blank, R | 1 |
| Messerli, FH | 1 |
| Bakris, GL | 1 |
| Ferrera, D | 1 |
| Houston, MC | 1 |
| Petrella, RJ | 1 |
| Flack, JM | 1 |
| Lee, E | 1 |
| Preston, RA | 1 |
| Herfert, O | 1 |
| Dykstra, G | 1 |
| Jukema, JW | 1 |
| Sun, F | 1 |
| Gillen, D | 1 |
| McKeage, K | 1 |
| Siddiqui, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Randomized, Double-blind, Parallel-group Phase III Clinical Trial to Evaluate the Efficacy and Safety of YHP1701 Fixed Dose Combination in Patients With Dyslipidemia and Hypertension[NCT03103256] | Phase 3 | 106 participants (Actual) | Interventional | 2017-05-17 | Completed | ||
| A Randomized, Double-blind, Active-controlled, Multicenter Phase3 Trial to Evaluate the Efficacy and Safety of Co-administrated Temisartan/Amlodipine and Rosuvastatin in Subjects With Hypertension and Hyperlipidemia[NCT03067688] | Phase 3 | 202 participants (Actual) | Interventional | 2017-04-11 | Completed | ||
| A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients With Dyslipidemia and Hypertension[NCT03088254] | Phase 3 | 126 participants (Actual) | Interventional | 2016-09-20 | Completed | ||
| Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study[NCT03047538] | Phase 4 | 0 participants (Actual) | Interventional | 2017-09-01 | Withdrawn (stopped due to Insufficient funds) | ||
| An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine/Atorvastatin Combination In Subjects With Hypertension And Dyslipidaemia. (The JEWEL II Study)[NCT00174304] | Phase 4 | 1,120 participants | Interventional | 2004-10-31 | Completed | ||
| An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine -Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL Study)[NCT00330785] | Phase 3 | 1,250 participants | Interventional | 2004-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for amlodipine and Dyslipidemias
| Article | Year |
|---|---|
Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases | 2009 |
Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseas | 2010 |
Atorvastatin calcium plus amlodipine for the treatment of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Drug Combinations; Dysl | 2012 |
A single-pill combination of amlodipine besylate and atorvastatin calcium.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blocker | 2006 |
Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Disease | 2008 |
17 trials available for amlodipine and Dyslipidemias
| Article | Year |
|---|---|
A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cholesterol, LDL; Double-Blind Method; Dyslipid | 2023 |
Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia.
Topics: Amlodipine; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Humans; Hypertension | 2023 |
A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; | 2020 |
Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinations; D | 2020 |
Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Double-Blind Me | 2019 |
Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asia; Calcium Channel Blockers; Cardiovascular Diseases; | 2014 |
[A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Coronary Disease; Dose-Response Relationship, D | 2014 |
Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardi | 2009 |
Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia.
Topics: Adult; Aged; Amlodipine; Arteries; Atorvastatin; Compliance; Drug Therapy, Combination; Dyslipidemia | 2009 |
The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study.
Topics: Amlodipine; Analysis of Variance; Atorvastatin; Calcium Channel Blockers; Double-Blind Method; Drug | 2009 |
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive A | 2009 |
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive A | 2009 |
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive A | 2009 |
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive A | 2009 |
Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Biomarker | 2010 |
The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin II Type 2 Receptor Blockers; Antihyperte | 2011 |
Improving adherence with amlodipine/atorvastatin therapy: IMPACT study.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black or African Americ | 2011 |
An additional LDL-lowering effect of amlodipine; not only an antihypertensive?
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium C | 2013 |
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.
Topics: Adolescent; Adult; Aged; Amlodipine; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholest | 2006 |
A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial.
Topics: Alanine Transaminase; Alkaline Phosphatase; Amlodipine; Anticholesteremic Agents; Antihypertensive A | 2007 |
12 other studies available for amlodipine and Dyslipidemias
| Article | Year |
|---|---|
Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; B | 2019 |
Fixed-dose combinations of lipid-lowering and antihypertensive agents: The way forward?
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Dyslipidemias; Humans; Hyp | 2020 |
Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Drug Combinations; Drug Therapy, Combination; Dys | 2020 |
[THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Therapy, Combination; Dysl | 2018 |
EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cholesterol; Ch | 2018 |
Fixed combination of amlodipine/atorvastatin: from mechanisms to trials.
Topics: Amlodipine; Anticholesteremic Agents; Calcium Channel Blockers; Cardiovascular Diseases; Drug Combin | 2013 |
Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database.
Topics: Amlodipine; Calcium Channel Blockers; Comorbidity; Drug Interactions; Drug Labeling; Drug Prescripti | 2015 |
Clinical Effectiveness, Safety and Tolerability of Amlodipine/Valsartan in Hypertensive Patients: the Indonesian Subset of the EXCITE Study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cough; Drug Combinations; Drug Sub | 2015 |
Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
Topics: Administration, Oral; Adult; Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Com | 2017 |
[How to increase the adherence to treatment of patients with arterial hypertension and dyslipidemia: focus on fixed combination of amlodipine and atorvastatin].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic | 2010 |
[Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia].
Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Viscosity; | 2010 |
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorv
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiov | 2006 |